PI-RADS v2.1
Nephrology and urology
Also known as: PI-RADS-Kategorien (Version 2.1) · PI-RADS v2.1 kategorileri · PI-RADS v2.1 assessment categories (prostate MRI)
What it is for
Five-point scale for the likelihood that a lesion on multiparametric prostate MRI is clinically significant prostate cancer (csPCa), built from T2-weighted (T2W), diffusion-weighted (DWI, with ADC) and dynamic contrast-enhanced (DCE) imaging.
Classification
| Category | Description |
|---|---|
| PI-RADS 1 | very low: csPCa highly unlikely. |
| PI-RADS 2 | low: csPCa unlikely. |
| PI-RADS 3 | intermediate: csPCa equivocal. |
| PI-RADS 4 | high: csPCa likely. |
| PI-RADS 5 | very high: csPCa highly likely. |
| Peripheral zone | DWI score is dominant; a DWI score 3 lesion with positive DCE (early focal enhancement matching the lesion) becomes PI-RADS 4. |
| Transition zone | T2W score is dominant; v2.1: a T2W score 2 (atypical) nodule becomes 3 when DWI is markedly restricted (DWI score ≥4); a T2W score 3 lesion becomes 4 when DWI score is 5. |
| Score 5 size rule | 4 versus 5 on T2W or DWI: a lesion ≥1.5 cm in greatest dimension, or definite extraprostatic extension or invasive behaviour, is 5. |
| PI-RADS X | a component is technically inadequate or missing. |
Source
Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2
ACR / ESUR / AdMeTech PI-RADS Steering Committee · Eur Urol 2019;76:340–351 (Turkbey B et al.)
DOI: 10.1016/j.eururo.2019.02.033
PMID: 30898406
- Edition
- PI-RADS v2.1 (2019; current ACR/ESUR version)
- Checked on
Summary of the published classification in our own words. Not a substitute for the original publication.
A question about this classification?
Medelix answers clinical questions from guidelines and studies – every statement with its source.